Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutogliptin vs placebo and sitagliptin in type 2 diabetes with moderate/severe renal impairment, including hemodialysis
2009-012213-22Phase 3Terminated
- Sponsor
- Phenomix Sciences
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dutogliptin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (3 arms), sponsored by Phenomix Sciences. Primary endpoints: Safety and tolerability, HbA1c change and 3 more. Started Sep 2009; status: terminated.
02
Drugs
dutogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2009-012213-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012213-22.